Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13373425 | 0.87 | ALDH1A1 (0.46) | ALDH1A1CYP3A4KDM4ESMN1; SMN2RAB9A | |
| SCHEMBL8794135 | 0.86 | ALDH1A1 (0.62) | ALDH1A1CYP3A4KDM4ESMN1; SMN2RAB9A | |
| SCHEMBL132773 | 0.85 | ALDH1A1 (0.78) | ALDH1A1CYP3A4KDM4EMAPTMEN1 | |
| SCHEMBL19564954 | 0.85 | ALDH1A1 (0.56) | ALDH1A1CYP3A4KDM4ESMN1; SMN2RAB9A | |
| SCHEMBL11839840 | 0.85 | RAB9A (0.46) | ALDH1A1CYP3A4KDM4ESMN1; SMN2RAB9A | |
| SCHEMBL28680322 | 0.85 | KDM4E (0.46) | ALDH1A1KDM4ESMN1; SMN2RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL11839850 | 0.83 | RAB9A (0.45) | ALDH1A1CYP3A4KDM4ESMN1; SMN2RAB9A | |
| SCHEMBL8794149 | 0.83 | ALDH1A1 (0.58) | ALDH1A1CYP3A4KDM4ESMN1; SMN2RAB9A | |
| SCHEMBL3136937 | 0.82 | KDM4E (0.42) | ALDH1A1KDM4ESMN1; SMN2RAB9ANPC1 | |
| SCHEMBL11743167 | 0.82 | KDM4E (0.45) | ALDH1A1KDM4ESMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240240226-A1 | FLUOROGENIC ASSAY FOR RAPID SCREENING OF BACTERIAL BETA-LACTAMASE ACTIVITY | UNIV LELAND STANFORD JUNIOR (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240240226-A1 | FLUOROGENIC ASSAY FOR RAPID SCREENING OF BACTERIAL BETA-LACTAMASE ACTIVITY | UNIV LELAND STANFORD JUNIOR (US) | 2024-07-18 | — | — | US | disclosed |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | US | disclosed |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2023-08-08 | — | — | US | disclosed |
| WO-2023091957-A1 | PEPTIDE CONJUGATES OF PEPTIDIC TUBULIN INHIBITORS AS THERAPEUTICS | CYBREXA 4, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-10010618-B2 | Methods for treating cancer using combination therapies | ENDOCYTE, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-9951324-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170320826-A1 | BIVALENT LINKERS AND CONJUGATES THEREOF | ENDOCYTE INC (US) | 2017-11-09 | — | — | US | disclosed |
| US-9782493-B2 | Conjugates for treating diseases caused by PSMA expressing cells | ENDOCYTE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20130158271-A1 | BIVALENT LINKERS AND CONJUGATES THEREOF | VLAHOV IONTCHO RADOSLAVOV (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130116195-A1 | Binding ligand linked drug delivery conjugates of tubulysins | LEAMON CHRISTOPHER PAUL (US) | 2013-05-09 | — | — | US | disclosed |
| US-20120322741-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2012-12-20 | — | — | US | disclosed |
| US-8288557-B2 | Bivalent linkers and conjugates thereof | ENDOCYTE, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120022245-A1 | FOLATE TARGETING OF NUCLEOTIDES | PURDUE RESEARCH FOUNDATION (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110172254-A1 | FOLATE RECEPTOR BINDING CONJUGATES OF ANTIFOLATES | ENDOCYTE, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110144163-A1 | THIOLATED PACLITAXELS FOR REACTION WITH GOLD NANOPARTICLES AS DRUG DELIVERY AGENTS | ZAHAV BIOSCIENCES LLC | 2011-06-16 | — | — | US | disclosed |
| US-20100324008-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100323973-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | ENDOCTYE, INC. | 2010-12-23 | — | — | US | disclosed |
| US-20090203889-A1 | Bivalent linkers and conjugates thereof | ENDOCYTE, INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | ALDH1A1 2843/4885CYP3A4 4369/4885KDM4E 3215/4885 |
| US-20120022245-A1 | FOLATE TARGETING OF NUCLEOTIDES | FOLR1, FOLR2, DHFR | ALDH1A1 1932/4885CYP3A4 4614/4885KDM4E 3509/4885 |
| US-20090203889-A1 | Bivalent linkers and conjugates thereof | CCNB2, PAICS, FOLR2 | ALDH1A1 1872/4885CYP3A4 587/4885KDM4E 1685/4885 |
| US-20130116195-A1 | Binding ligand linked drug delivery conjugates of tubulysins | TEK, TEKT1, CD2BP2 | ALDH1A1 4745/4885CYP3A4 4864/4885KDM4E 3346/4885 |
| US-10010618-B2 | Methods for treating cancer using combination therapies | SLC7A11, CXCR2, TPX2 | ALDH1A1 831/4885CYP3A4 3409/4885KDM4E 2811/4885 |
| US-20120322741-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | ALDH1A1 2748/4885CYP3A4 4387/4885KDM4E 3111/4885 |
| US-20100324008-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | ALDH1A1 2843/4885CYP3A4 4369/4885KDM4E 3215/4885 |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | ALDH1A1 2843/4885CYP3A4 4369/4885KDM4E 3215/4885 |
| US-20240240226-A1 | FLUOROGENIC ASSAY FOR RAPID SCREENING OF BACTERIAL BETA-LACTAMASE ACTIVITY | CDA, CMBL, CTSF | ALDH1A1 203/4885CYP3A4 560/4885KDM4E 2894/4885 |
| US-20100323973-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | CD44, HAVCR2, HCAR1 | ALDH1A1 2723/4885CYP3A4 4431/4885KDM4E 4752/4885 |
| US-20130158271-A1 | BIVALENT LINKERS AND CONJUGATES THEREOF | PAICS, FOLR2, DCLRE1A | ALDH1A1 2328/4885CYP3A4 2690/4885KDM4E 3584/4885 |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | ALDH1A1 2843/4885CYP3A4 4369/4885KDM4E 3215/4885 |
| US-20110144163-A1 | THIOLATED PACLITAXELS FOR REACTION WITH GOLD NANOPARTICLES AS DRUG DELIVERY AGENTS | TUBB6, TUBB1, TUBB | ALDH1A1 189/4885CYP3A4 391/4885KDM4E 4424/4885 |
| US-20170320826-A1 | BIVALENT LINKERS AND CONJUGATES THEREOF | PAICS, FOLR2, DCLRE1A | ALDH1A1 2328/4885CYP3A4 2690/4885KDM4E 3584/4885 |
| US-20110172254-A1 | FOLATE RECEPTOR BINDING CONJUGATES OF ANTIFOLATES | FOLR1, FOLR2, DHFR | ALDH1A1 1044/4885CYP3A4 3643/4885KDM4E 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.